WHO ICTRP trial
Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive…
NCT03910270 · NIH Clinical Trials · Not recruiting
Key facts
| Trial ID | NCT03910270 |
|---|---|
| Public title | Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer |
| Scientific title | A Phase Ib, Open-label, Single Center, Non-randomized Study for Safety and Efficacy of TQB2450 Combined With Anlotinib in Patients With Advanced Mutation Positive Non-Small Cell Lung Cancer |
| Primary sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Registry | NIH Clinical Trials |
| Recruitment status | Not recruiting |
| Study type | Interventional |
| Phase | Phase 1 |
| Conditions | Lung Cancer |
| Interventions | Drug: TQB2450;Drug: Anlotinib |
| Registration date | Sep 4, 2019 |
| Target size | 30 |
| Secondary IDs | TQB2450-Ib-11 |
| Registry page | clinicaltrials.gov |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: